Phase 1/2 Study of GCS-100 in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B Cell Lymphoma.

Trial Profile

Phase 1/2 Study of GCS-100 in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B Cell Lymphoma.

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2013

At a glance

  • Drugs GCS 100 (Primary) ; Dexamethasone; Etoposide
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 25 Jan 2012 Status changed from suspended to withdrawn prior to recruitment.
    • 20 May 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 12 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top